Drug-induced anaphylaxis: Analysis of the Pharmacovigilance Database

Sujeong Kim; Han-Ki Park

doi:10.4168/aard.2020.8.1.1

Journal List > Allergy Asthma Respir Dis > v.8(1) > 1141940

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Park: Drug-induced anaphylaxis: Analysis of the Pharmacovigilance Database

Editorial

Allergy, Asthma & Respiratory Disease 2020; 8(1): 1-2.

Published online: 31 January 2020

DOI: https://doi.org/10.4168/aard.2020.8.1.1

Drug-induced anaphylaxis: Analysis of the Pharmacovigilance Database

Sujeong Kim

, Han-Ki Park

Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.

Correspondence to: Sujeong Kim. Department of Internal Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. Tel: +82-53-200-6570, Fax: +82-53-426-2046, sjk@knu.ac.kr

Received 29 November 2019 Revised 22 December 2019 Accepted 23 December 2019

The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

References

1. Ye YM, Kim MK, Kang HR, Kim TB, Sohn SW, Koh YI, et al. Predictors of the severity and serious outcomes of anaphylaxis in Korean adults: a multicenter retrospective case study. Allergy Asthma Immunol Res. 2015; 7:22–29.

2. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009; 123:434–442.

3. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, et al. Epidemiologic and clinical features of anaphylaxis in Korea. Ann Allergy Asthma Immunol. 2008; 100:31–36.

4. Park HK, Kang MG, Yang MS, Jung JW, Cho SH, Kang HR. Epidemiology of drug-induced anaphylaxis in a tertiary hospital in Korea. Allergol Int. 2017; 66:557–562.

5. Ribeiro-Vaz I, Marques J, Demoly P, Polónia J, Gomes ER. Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol. 2013; 69:673–681.

6. Zhao Y, Sun S, Li X, Ma X, Tang H, Sun L, et al. Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database. Int J Clin Pharm. 2018; 40:1349–1358.

7. Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, et al. Drug-induced anaphylaxis in a Vietnamese Pharmacovigilance Database: trends and specific signals from a disproportionality analysis. Drug Saf. 2019; 42:671–682.

8. Cho MK, Moon M, Kim HH, Kang DY, Lee JY, Cho SH, Kang HR. Analysis of individual case safety reports of drug-induced anaphylaxis to the Korea Adverse Event Reporting System. Allergy Asthma Respir Dis. 2020; 8:30–35.

9. Park KH, Pai J, Song DG, Sim DW, Park HJ, Lee JH, et al. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing. Clin Exp Allergy. 2016; 46:631–639.

10. Bouzillé G, Osmont MN, Triquet L, Grabar N, Rochefort-Morel C, Chazard E, et al. Drug safety and big clinical data: detection of drug-induced anaphylactic shock events. J Eval Clin Pract. 2018; 24:536–544.

TOOLS

ORCID iDs: Sujeong Kim
https://orcid.org/0000-0002-2494-9216
Similar articles